Jill M. Williams

Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report

Douglas Ziedonis, Brian Hitsman, Jean C. Beckham et al. · Nicotine & Tobacco Research · 2008 · 728 citations · Full text

Tobacco Cessation, Substance Use, National Institute +20

Design, synthesis and characterization of novel 2-(2,4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of NF-κB and AP-1 mediated transcription activation and as potential anti-inflammatory agents

Rajan Giri, Hardik M. Thaker, Tony Giordano et al. · European Journal of Medicinal Chemistry · 2008 · 164 citations · Full text

Medicinal Chemistry, -3-Aryl-3h-quinazoline-4-one Derivatives, Anti-inflammatory +11

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Patients With Schizophrenia or Schizoaffective Disorder

Jill M. Williams, Robert M. Anthenelli, Chad D. Morris et al. · The Journal of Clinical Psychiatry · 2012 · 161 citations

Lower quit rates among African American and Latino menthol cigarette smokers at a tobacco treatment clinic

Kavita Gandhi, Jonathan Foulds, Michael Steinberg et al. · International Journal of Clinical Practice · 2009 · 155 citations

Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect

Jill M. Williams, Douglas Ziedonis, Francisca Abanyie et al. · Schizophrenia Research · 2005 · 152 citations

Tobacco Control, Substance Abuse, Psychiatry +11